Advances in Migraine Treatment (worldwide)
The Advances in Migraine Treatment grant funded by Pfizer supports educational programs worldwide that increase the understanding of healthcare professionals on the management and care of people with migraine. Pfizer is interested in educational initiatives that encompass the following:
- Unmet need and disease burden associated with migraine
- The role of CGRP in the pathophysiology of migraine
- Anti-CGRP therapies for acute and prophylactic treatment of migraine
Applicants may be from medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement, worldwide, except for those based in the USA. Applicants may apply for up to 250,000 USD for up to 2 years in funding support, including up to 28% in overhead costs. Applications close on October 11, 2022.
Create or sign in to your free account for more functionalities, including a full display of the eligibility criteria such as location and citizenship requirements.